H.C. Wainwright Remains Bullish on Eton Pharmaceuticals’ (ETON) Growth Strategy
Key takeaways
- Wainwright Remains Bullish on Eton Pharmaceuticals’ (ETON) Growth Strategy Noor Ul Ain Rehman Sat, May 23, 2026 at 7:16 PM GMT+7 2 min read ETON Eton Pharmaceuticals, Inc.
- The rating update came after Eton Pharmaceuticals, Inc.
- (NASDAQ:ETON) is a pharmaceutical company that develops and sells treatments for rare diseases.
H.C. Wainwright Remains Bullish on Eton Pharmaceuticals’ (ETON) Growth Strategy Noor Ul Ain Rehman Sat, May 23, 2026 at 7:16 PM GMT+7 2 min read ETON Eton Pharmaceuticals, Inc. (NASDAQ:ETON) is one of the best oversold growth stocks to invest in now. H.C. Wainwright lifted the price target on Eton Pharmaceuticals, Inc. (NASDAQ:ETON) to $57 from $52 on May 15, reaffirming a Buy rating on the shares and citing the company’s elevated fiscal 2026 revenue guidance and confidence in its growth strategy for the target bump. The firm further told investors in a research note that the company’s stated long-term goals could be achievable, given its execution to date.
The rating update came after Eton Pharmaceuticals, Inc. (NASDAQ:ETON) reported its fiscal Q1 2026 results on May 14, reporting product sales of $24.3 million for the quarter, reflecting a 73% growth over Q1 2025. It also raised its full-year revenue guidance, and now anticipates 2026 revenue to surpass $120 million, up from previous guidance of $110 million. The company further reported that fiscal Q1 2026 fully diluted GAAP EPS was $0.05, non-GAAP fully diluted EPS was $0.14, and adjusted EBITDA reached $5.7 million. Eton Pharmaceuticals, Inc. (NASDAQ:ETON) also received FDA approval for and launched DESMODA™, while also acquiring and relaunching HEMANGEOL®.
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) is a pharmaceutical company that develops and sells treatments for rare diseases. The company focuses on bringing therapies to patients with limited treatment options.